PubMed=181343; DOI=10.1159/000149930
Klein G., Giovanella B.C., Westman A., Stehlin J.S. Jr., Mumford D.M.
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Intervirology 5:319-334(1975)

PubMed=175026; DOI=10.1002/ijc.2910170203
Fresen K.-O., zur Hausen H.
Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Int. J. Cancer 17:161-166(1976)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

PubMed=6286763
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2835030; DOI=10.1016/s0385-8146(87)80025-1
Takimoto T., Sato H., Ogura H., Miyazaki T.
Establishment of an Epstein-Barr virus (EBV) genome-positive subline of Ramos (Ramos/NPC) following infection of Ramos with nasopharyngeal carcinoma (NPC)-derived EBV.
Auris Nasus Larynx 14:87-92(1987)

PubMed=3026973; DOI=10.1002/ijc.2910390215
Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.
Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.
Int. J. Cancer 39:211-218(1987)

PubMed=1850347; DOI=10.1210/endo-128-5-2266
Baglia L.A., Cruz D., Shaw J.E.
An Epstein-Barr virus-negative Burkitt lymphoma cell line (sfRamos) secretes a prolactin-like protein during continuous growth in serum-free medium.
Endocrinology 128:2266-2272(1991)

PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8402660
O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T., Kohn K.W.
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.
Cancer Res. 53:4776-4780(1993)

PubMed=8515068
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=7757991
Bae I., Fan S., Bhatia K.G., Kohn K.W., Fornace A.J. Jr., O'Connor P.M.
Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Cancer Res. 55:2387-2393(1995)

PubMed=8896424; DOI=10.1182/blood.V88.9.3562.bloodjournal8893562
Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.
VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection.
Blood 88:3562-3568(1996)

PubMed=9192833
Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.
Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.
Cancer Res. 57:2508-2515(1997)

PubMed=9225077; DOI=10.1016/S0145-2126(97)00126-4
Okano M.
High susceptibility of an Epstein-Barr virus-converted Burkitt's lymphoma cell line to cytotoxic drugs.
Leuk. Res. 21:469-471(1997)

PubMed=9473234; DOI=10.1182/blood.V91.5.1680
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

PubMed=9973220
Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.
Leuk. Res. 24:255-262(2000)

PubMed=10918597; DOI=10.1038/sj.onc.1203686
Bemark M., Neuberger M.S.
The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.
Oncogene 19:3404-3410(2000)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1
Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.
Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000),255-262.
Leuk. Res. 25:275-278(2001)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)

PubMed=18211290; DOI=10.1111/j.1365-2184.2007.00500.x
Zander L., Bemark M.
Identification of genes deregulated during serum-free medium adaptation of a Burkitt's lymphoma cell line.
Cell Prolif. 41:136-155(2008)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161
Maria Murga Penas E., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.
Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.
Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)